U.S. markets closed
  • S&P 500

    3,768.25
    -27.29 (-0.72%)
     
  • Dow 30

    30,814.26
    -177.24 (-0.57%)
     
  • Nasdaq

    12,998.50
    -114.10 (-0.87%)
     
  • Russell 2000

    2,123.20
    -32.15 (-1.49%)
     
  • Crude Oil

    52.04
    -1.53 (-2.86%)
     
  • Gold

    1,827.70
    -23.70 (-1.28%)
     
  • Silver

    24.83
    -0.97 (-3.77%)
     
  • EUR/USD

    1.2085
    -0.0071 (-0.58%)
     
  • 10-Yr Bond

    1.0970
    -0.0320 (-2.83%)
     
  • GBP/USD

    1.3583
    -0.0108 (-0.79%)
     
  • USD/JPY

    103.6890
    -0.1270 (-0.12%)
     
  • BTC-USD

    35,936.00
    +935.34 (+2.67%)
     
  • CMC Crypto 200

    701.93
    -33.21 (-4.52%)
     
  • FTSE 100

    6,735.71
    -66.25 (-0.97%)
     
  • Nikkei 225

    28,519.18
    -179.12 (-0.62%)
     

Is Allogene Therapeutics (ALLO) Stock Outpacing Its Medical Peers This Year?

Zacks Equity Research
·2 min read

Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Has Allogene Therapeutics (ALLO) been one of those stocks this year? Let's take a closer look at the stock's year-to-date performance to find out.

Allogene Therapeutics is one of 894 individual stocks in the Medical sector. Collectively, these companies sit at #1 in the Zacks Sector Rank. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.

The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. ALLO is currently sporting a Zacks Rank of #2 (Buy).

Over the past three months, the Zacks Consensus Estimate for ALLO's full-year earnings has moved 4.16% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.

According to our latest data, ALLO has moved about 0.31% on a year-to-date basis. At the same time, Medical stocks have lost an average of 5.70%. This shows that Allogene Therapeutics is outperforming its peers so far this year.

To break things down more, ALLO belongs to the Medical - Biomedical and Genetics industry, a group that includes 384 individual companies and currently sits at #20 in the Zacks Industry Rank. Stocks in this group have lost about 1.93% so far this year, so ALLO is performing better this group in terms of year-to-date returns.

Investors with an interest in Medical stocks should continue to track ALLO. The stock will be looking to continue its solid performance.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Allogene Therapeutics, Inc. (ALLO) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.